Reactivation of hepatitis B: Pathogenesis and clinical implications

被引：27

作者：

Post A. ^{[1
]}

Nagendra S. ^{[1
]}

机构：

[1] Case Medical Center, University Hospitals, Cleveland, OH 44106

来源：

Current Infectious Disease Reports | 2009年 / 11卷 / 2期

关键词：

Lamivudine; Positive HBeAg; Lamivudine Prophylaxis; Prophylactic Lamivudine; Preemptive Lamivudine;

D O I：

10.1007/s11908-009-0017-3

中图分类号：

学科分类号：

摘要：

Chronic hepatitis B virus (HBV) is estimated to be present in 350 million people worldwide. One of its major complications is reactivation of dormant HBV, which is associated with significant morbidity and mortality. Although reactivation can occur spontaneously, the most common risk factor is initiation of immunosuppression. As the use of immunosuppressive therapy increases, the incidence of HBV reactivation is expected to rise. Screening with serologic markers for hepatitis B is recommended before initiating immunosuppressive therapy. In patients with no evidence of HBV infection, immunization is recommended. In chronic carriers, prophylactic antiviral treatment has been shown to decrease overall morbidity and mortality. Patients with inactive HBV should be monitored closely during immunosuppressive treatment with alanine transaminase and serum HBV-DNA levels and treated promptly if they develop HBV reactivation. Although HBV reactivation is a serious complication, it can be prevented with screening and prophylactic treatment. © Current Medicine Group, LLC 2009.

引用

页码：113 / 119

页数：6

共 41 条

[1]

Lalazar G., Rund D., Shouval D., Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies, Br J Haematol, 136, pp. 699-712, (2007)

[2]

Yeo W., Johnson P., Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy, Hepatology, 43, pp. 209-220, (2006)

[3]

Mindikoglu A., Regev A., Schiff E., Hepatitis B virus reactivation after cytotoxic chemotherapy: The disease and prevention, Clin Gastroenterol Hepatol, 4, pp. 1076-1081, (2006)

[4]

Calabrese L., Zein N., Vassilopoulos D., Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic disease: Assessment and preventive strategies, Ann Rheum Dis, 65, pp. 983-989, (2006)

[5]

Lavanchy D., Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measure, J Viral Hepatitis, 11, pp. 97-107, (2004)

[6]

Perrillo R., Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically medicated liver disease, Gastroenterology, 120, pp. 1009-1022, (2001)

[7]

Kohrt H., Ouyang D., Keeffe E., Systematic review: Lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection, Aliment Pharmacol Ther, 24, pp. 1003-1016, (2006)

[8]

Esteve M., Saro C., Gonzalez-Huix, Et al., Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: Need for primary prophylaxis, Gut, 53, pp. 1363-1365, (2004)

[9]

Tsai F., Hsieh S., Chen D., Et al., Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents, Dig Dis Sci, 51, pp. 1627-1632, (2006)

[10]

Yeo W., Chan P., Zhong S., Et al., Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors, J Med Virol, 62, pp. 299-307, (2000)

← 1 2 3 4 5 →